Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer

Abstract

Compared with observation and other agents used and/or reimbursed for maintenance therapy in advanced NSCLC, Pem may be considered cost-effective, particularly in patients with nonsquamous cell histology. This analysis is the first to evaluate the cost-effectiveness of maintenance therapy in advanced NSCLC and emphasizes the importance of histology in identifying the appropriate patient for Pem maintenance therapy.

Antineoplastic Treatment of Advanced-Stage Non–Small-Cell Lung Cancer: Treatment, Survival, and Spending (2000 to 2011)

“…7 Pemetrexed has an incremental cost-effectiveness ratio of $122,371 per life-year gained compared with observation with best supportive care. 8 Erlotinib added to standard chemotherapy regimens has a cost-effectiveness ratio of $95,000 per quality-adjusted life-year relative to standard regimens alone. 9 With the use of data from linked SEERregistry Medicare claims files, this study evaluated infusion and oral antineoplastic agents prescribed for newly diagnosed advanced-stage NSCLC over a 12-year period.…”

Le coût du traitement des cancers bronchopulmonaires non à petites cellules (CBNAPC)

“…L'un a été publié par Klein en 2010 [18]. Cet article est le premier article médico-économique sur l'utilisation d'un produit en maintenance dans le CBP.…”

Screening for Patients with Non-small Cell Lung Cancer Who Could Survive Long Term Chemotherapy

“…Some studys showed non-inferior efficacy and better tolerability for pemetrexed plus cisplatin than for cisplatin plus other chemotherapy agents e.g., gemcitabine or docetaxel especially, for patients with adenocarcinoma (Reck et al, 2009;Scagliotti et al, 2009;Klein et al, 2010). In recent years, Erlotinib has been approved in more than 80 countries for the treatment of NSCLC patients who have received at least one prior chemotherapy (Mok et al, 2010;Reck et al, 2010).…”